Supernus Pharmaceuticals | SUPN - Cost Of Sales

Stock Price
52.07
Daily Change
0.46 0.89%
Monthly
-2.98%
Yearly
67.59%
Q2 Forecast
48.96

Supernus Pharmaceuticals reported $47.53M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Abbott USD 4.92B 535M Dec/2025
ANI Pharmaceuticals USD 122.88M 6.86M Dec/2025
Aurora Cannabis CAD 88.61M 30.53M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Canopy Growth CAD 53.08M 8.3M Dec/2025
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 2.54M 2.05M Dec/2025
Eisai JPY 51.08B 5.56B Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Novo Nordisk DKK 15.15B 2.3B Dec/2025
Pacira USD 54.62M 6.02M Dec/2025
Perrigo USD 747.4M 81.2M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
Supernus Pharmaceuticals USD 47.53M 4.24M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Xeris Pharmaceuticals USD 13.66M 49K Dec/2025